Research Use Limitation Used solely for in vitro experiments Not permitted for clinical trials involving humans Not permitted for human or veterinary administration Not permitted for investigational human use Independent third-party laboratory verification by Liquilabs s.r.o
Comment: A commenter requested additional clarification regarding the figures in Table 111 of the CY 2026 OPPS/ASC proposed rule
Section 1833(t)(3)(F)(i) of the Act reduces that 3.3 percent by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act, which is a 0.7 percentage point for CY 2026 (which is also the productivity adjustment for FY 2026 in the FY 2026 IPPS/LTCH PPS proposed rule (90 FR 18257)) resulting in the proposed CY 2026 OPD fee schedule increase factor of 2.6 percent
Take the Next Step with Dr
Section 1833(t)(9)(A) of the Act requires the Secretary to review certain components of the OPPS, not less often than annually, and to revise the groups, the relative payment weights, and the wage and other adjustments to take into account changes in medical practices, changes in technology, the addition of new services, new cost data, and other relevant information and factors
Long-term continuous use without breaks may lead to reduced effectiveness
